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The aim of this study was to evaluate the clinical signiﬁcance of serum bepridil (Bep) concentration
(SBC) for safely managing patients with atrial tachyarrhythmias (AT).
Methods and results: SBC was measured in 37 patients with AT, including atrial fribrillation (AF) (31
cases), AFþatrial ﬂutter (AFL) (4 cases), AFL (1 case), and atrial tachycardia (1 case). The patients were
administrated Bep for more than 4 weeks at the same dose. SBC was positively correlated with Bep dose
per kilogram of body weight (p¼0.015), QT interval (p¼0.019), and QTc (p¼0.034). The patients
were divided into 2 groups according to their SBC: the high-SBC (HSBC) group of 8 patients with
an SBCZ500 ng/ml and a low-SBC (LSBC) group of 29 patients with an SBCo500 ng/ml. There was no
difference in maintenance of sinus rhythm between the groups. For clinical variables, QT and QTc were
signiﬁcantly longer in the HSBC than in the LSBC group (p¼0.004 and p¼0.016, respectively). Patients
with QT40.5 were more prominent in the HSBC group (37.5% vs. 3.4%, p¼0.026), and torsade de points
(TdP) occurred in only one patient in the HSBC group. However, there were several patients with
normal QT/QTc despite having high SBC.
Conclusions: In patients treated with Bep, measurement of SBC is useful for preventing proarrhythmias.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Bepridil (Bep) has been reported to be effective for treating
persistent atrial ﬁbrillation (AF), and atrial ﬂutter (AFL) by
converting and maintaining sinus rhythm [1–8]. In addition, a
reverse remodeling effect in the atrium has been recognized in
animal models of AF [9,10]. However, serious adverse effects have
been noted in clinical trials [11–14]. In particular, torsarde de
points (TdP) with marked QT prolongation is a life-threatening
event. Yasuda et al. [11] reported adverse effects in 4% of the
patients treated with Bep and Tdp in 0.9% of these patients. In the
J-BAF study [15], although Bep effectively maintained sinus
rhythm, there was a high recurrence rate of AF and one case of
sudden cardiac death. Therefore, it remains important to carefully
consider the safety of Bep when selecting a rhythm control
strategy. Kurita et al. [16] reported that Tdp occurred in patientsrt Rhythm Society. Published by E
x: þ81 03 5923 3217.
hi).with a serum Bep concentration (SBC)Z500 ng/ml. Recently, SBC
was suggested to be useful for selecting the maintenance dose of
Bep [17–19]. However, very limited data on this issue are available.
The aim of this study was to evaluate the clinical signiﬁcance
of SBC for the safe management of patients with atrial tachy-
arrhythmia (AT).2. Methods
We measured the SBC of 45 consecutive patients treated with
Bep between July 9, 2008 and April 28, 2009. Of these patients,
two patients were excluded from the evaluation because a
12-lead electrocardiogram (ECG) was not performed on the same
day as SCB measurement. Another 2 patients who had been taking
Bep for less than 4 weeks and 4 patients with ventricular pacing
were also excluded from the study. Therefore, the study popula-
tion consisted of 37 patients. All patients were administrated
Bep for more than 4 weeks and continued Bep treatment at the
same dose for at least 4 additional weeks. Their AT included AFlsevier B.V. All rights reserved.
Table 1
Clinical characteristics of the study patients.
Number 37
Age (years) 68.879.6
Gender (M/F) 26/11
Height (cm) 161710
Body weight (kg) 60.5711.2
Dose of bepridil (mg) 134749
Bepridil dose/body weight (mg/kg) 2.2470.82
Serum bepridil concentration (ng/ml) 4157375
Unerlying cardiovascular disease
None 13
Hypertension 22
Hypertensive heart disease (mild LVH) 2
Sick sinus syndrome with pacemaker 4
Valvular heart disease 2
Congenital heart disease 1
Post-ablation of atrial ﬂutter 1
Other disorders
Diabetes 4
Dyslipidemia 7
Chronic lung disease 1
Rhematoid arthritis 1
Combined medication
Class I anti-arrhythmic drug (Ic) 1
Digoxin 6
Beta-blocker 11
Verapamil 6
ACEI or ARB 17
Statins 7
Diuretics 4
Liver and renal function
ALT (GPT) (IU/L) 29.5732.3
GFR 69.5716.2
Serum potassium (mmol/L) 4.270.3
Echocardiographic parameters
LVEF (%) 70.074.8
Left atrial dimension (mm) 39.275.5
ECG parameters at SBC measurement
Rhythm at ECG recording
Sinus 30
Atrial ﬁbrillation 4
Atrial pacing 3
LVH: left ventricular hypertrophy; ACEI: angiotensin converting enzyme inhibitor;
ARB: angiotensin II receptor blocker, GFR: glomerular ﬁltration rate; LVEF: left
ventricular ejection fraction; SBC: serum bepridil concentration.
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(1 case).
The study protocol was approved by the ethics committee at
Juntendo University Nerima Hospital. After informed consent was
obtained, SBC measurement was performed using a blood sample
from each participant. Plasma was separated from each sample
immediately after collection by centrifugation at 3000 rpm for
10–15 min. All samples were stored at 20 1C and were trans-
ferred on dry ice to Daiichi Sankyo RD Associe Co. Ltd., Tokyo,
Japan. Each sample was thawed slowly at room temperature, and
SBC was determined using high-performance liquid chromato-
graphy (HPLC). The SBC was measured twice in 3 patients who
had changed their dose of Bep at least 4 weeks prior to the second
sampling. The data for each of these 3 patients were evaluated at
each sampling.
The relationships between SBC and age, gender, body weight, liver
function, renal function, underlying cardiovascular disease, cardiac
function (i.e., left ventricular ejection fraction (LVEF) and left atrial
dimension (LAD) examined by echocardiography), Bep dose, Bep dose
per kilogram of body weight, and ECG parameters (RR interval, QRS
duration, QT interval, and QTc) were studied. The glomerular ﬁltration
rate (GFR) was calculated as eGFR by the following formula: eGFR
(ml/min/1.73 m2)¼0.7415 age0.203 serum creatinine1.154.
For female patients, the value was multiplied by 0.742. In all patients,
12-lead ECG was recorded with standard gain (0.1 mV/mm) at a
recording speed of 25 mm/s on the same day as SBC measurement.
The ECG parameters were measured or determined by 2 blinded
investigators. When the decisions differed between them, the con-
clusion was made by a third blinded investigator.
In addition, we divided the patients into two groups according to
their SBC: a high-SBC (HSBC, SBCZ500 ng/ml) and a low-SBC (LSBC,
SBCo500 ng/ml) group. The cutoff point was determined as
500 ng/ml according to a report by Kurita et al. [16]. We also
compared the clinical variables between the HSBC and LSBC groups.
2.1. Statistical analysis
Continuous variables are presented as the mean7SD and were
compared using the unpaired Student’s t test or the Mann–
Whitney’s U test. Categorical variables were compared using the
w2 test or Fisher’s exact test. The relationships between SBC and
clinical variables or ECG parameters were performed using the
Pearson correlation coefﬁcient. A p-value ofo0.05 was consid-
ered statistically signiﬁcant.3. Results
3.1. Patient characteristics
The clinical characteristics of the patients in this study are
provided in Table 1. There were 26 men and 11 women with an
age range of 44–90 years (average 68.479.6). Underlying cardi-
ovascular disease was observed in 24 patients. Lone AF was
diagnosed in 13 patients. Left ventricular systolic function was
normal in all patients with a LVEF of more than 60% on
echocardiography. At the time of SBC measurement, sinus rhythm
was recorded in 30 patients, AF in 4 patients, and atrial pacing in
3. The mean dose of Bep was 134749 mg, and the mean Bep dose
per kilogram of body weight was 2.2470.82 mg/kg. The mean
SBC was 4157375 ng/ml.
3.2. Correlation of SBC with clinical variables
In this study, SBC was not correlated with age, body weight,
ALT, GFR, LVEF, or LAD. Although SBC was not signiﬁcantly relatedto Bep dose (r¼0.268, p¼0.11), SBC was correlated with Bep dose
per kilogram of body weight (r¼0.393, p¼0.015) (Fig. 1). Regard-
ing the ECG parameters, SBC was signiﬁcantly correlated with QT
interval (r¼0.383, p¼0.019) (Fig. 2) and QTc (r¼0.348, p¼0.034)
(Fig. 3). In addition, SBC was not related to the RR interval or QRS
duration.
3.3. Comparison of clinical variables between high- and low-SBC
groups
The HSBC group consisted of 8 patients, and the LSBC group
included 29 patients. The results of the comparison between the
two groups are provided in Table 2. Age, gender, ALT, GFR, and the
dose of Bep did not differ between the groups. Body weight was
lower in the HSBC group than in the LSBC group (53.5714.6 vs.
62.479.5, p¼0.047). Neither dose of Bep nor Bep dose per
kilogram of body weight (mg/kg) differed between the groups
(138752 vs. 133749, p¼0.81; 2.5470.66 vs. 2.1670.85, p¼0.25,
respectively). Maintenance of sinus rhythm (or atrial pacing) was
observed in 8 patients (100%) in the HSBC group and 25 patients
(86%) in the LSBC group upon SBC measurement. The groups
did not signiﬁcantly differ. The QT interval was signiﬁcantly
Fig. 1. Correlation between serum bepridil (Bep) concentration (SBC) and Bep
dose per kilogram of body weight. SBC was weakly correlated with Bep dose per
body weight (r¼0.393, p¼0.015).
Fig. 2. Correlation between serum bepridil concentration (SBC) and QT interval.
SBC was signiﬁcantly correlated with QT interval (r¼0.383, p¼0.019).
Fig. 3. Correlation between serum bepridil concentration (SBC) and QTc. SBC was
correlated with QTc (r¼0.348, p¼0.034).
Table 2
Comparison of clinical variables between high and low SBC groups.
High SBC Low SBC p value
Number 8 29
Age (years) 70.0712.8 68.578.8 NS
Gender (M/F) 4/4 22/7 NS
Body weight (kg) 53.5714.6 62.479.5 0.047
Dose of bepridil (mg) 138752 133749 NS
Bepridil dose/body weight (mg/kg) 2.5470.66 2.1670.85 NS
Serum bepridil concentration (ng/ml) 10137381 2507120 –
Unerlying cardiovascular disease
None 4 9 NS
Hypertension 4 18 NS
Hypertensive heart disease (mild LVH) 0 2
Sick sinus syndrome with pacemaker 1 3
Valvular heart disease 1 1
Congenital heart disease 0 1
Post-ablation of atrial ﬂutter 0 1
Other disorders
Diabetes 0 4
Dyslipidemia 1 6
Chronic lung disease 0 1
Rhematoid arthritis 1 0
Combined medication
Class I anti-arrhythmic drug 0 1
Digoxin 2 4
Beta-blocker 2 9
Verapamil 3 3
ACEI or ARB 3 14
Statins 1 6
Diuretics 1 3
Liver and renal function
ALT (GPT) (IU/L) 24.3711.6 31.0736.0 NS
GFR 66.0717.3 70.5716.0 NS
Serum potassium (mmol/L) 4.2170.42 4.1970.27 NS
Echocardiographic parameters
LVEF (%) 71.575.0 69.674.7 NS
Left atrial dimension (mm) 36.375.9 40.175.2 NS
ECG parameters before bepridil administration
Rhyrhm
Sinus
Atrial ﬁbrillation
Atrial pacing
RR inereval (s) 0.9070.22 0.8270.18 NS
QRS duration (s) 0.0870.01 0.0970.02 NS
QT (s) 0.3870.07 0.3970.05 NS
QTc 0.4070.04 0.4370.02 0.006
ECG parameters at SBC measurement
Maintenance of sinus rhythma 8 (100%) 25 (86%) NS
Rhythm
Sinus 7 23 NS
Atrial ﬁbrillation 0 4
Atrial pacing 1 2
RR inereval (s) 1.0370.15 0.9570.18 NS
QRS duration(s) 0.0870.01 0.0970.02 NS
QT (s) 0.5170.10 0.4370.05 0.004
QTc 0.5070.10 0.4570.04 0.016
QT40.5 3 (37.5%) 1 (3.4%) 0.026
SBC: serum bepridil concentration; LVH: left ventricular hypertrophy, ACEI:
angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker,
GFR: glomerular ﬁltration rate; LVEF: left ventricular ejection fraction.
a Including atrial pacing.
S. Miura et al. / Journal of Arrhythmia 28 (2012) 187–191 189longer in the HSBC group than in the LSBC group (0.5170.10 vs.
0.4370.05, p¼0.004). In the HSBC group, QTc was shorter before
administration of Bep (0.4070.04 vs. 0.4370.02, p¼0.006), but
it was signiﬁcantly longer at SBC measurement (0.5070.10 vs.
0.4570.04, p¼0.016). More patients with a QT40.5 were
observed in the HSBC group than in the LSBC group (37.5% vs.
3.4%, p¼0.026), and TdP occurred in one patient in the HSBC
group.3.4. Case presentation
A 90-year-old female had been treated for hypertension.
Echocardiography showed mild regurgitation of the mitral valve
with normal LV contraction (LVEF 70%). The patient had been
taking Bep at a dose of 100 mg/day for paroxysmal AF for 28
months. The Bep dose per kilogram of body weight was 2.7 mg/kg.
The patient had an episode of Tdp together with a low serum
Fig. 4. The ﬁgure shows an electrocardiogram (ECG) from a 90-year-old female patient suffering from torsade de points (TdP), who had been taking bepridil at a dose of
100 mg/day for paroxysmal atrial ﬁbrillation. Tdp occurred with a low serum potassium level of 3.3 mmol/L (left). Two hours after the Tdp episode, the patient’s ECG
showed QT prolongation: the patient’s QT interval and QTc were 0.62 s and 0.63, respectively, and there were marked U waves in V3,4 and a fused U or T–U complex in V5
(right). The patient’s serum bepridil concentration when the Tdp episode occurred was high at 1275 ng/ml.
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the Tdp episode, the patient’s ECG showed sinus rhythm with
QT(U) prolongation: the QT interval and QTc were 0.62 s and 0.63,
respectively, and marked U waves were observed in V3,4 with a
fused U or T–U complex in V5 (Fig. 4, right). Her SBC at the time of
the Tdp episode was high at 1275 ng/ml.Fig. 5. The relationship between mean dose of bepridil and mean serum bepridil
concentration (SBC) in the previous studies [16–18,20] and our study.4. Discussion
We demonstrated that SBC was positively correlated with QT
interval and QTc, and the HSBC group had a longer QT interval and
included more patients with a QT interval40.5 s compared to the
LSBC group. Measurement of the SBC appears useful for prevent-
ing proarrhythmias.
4.1. Cutoff point of SBC for safe management
Kurita et al. [16] reported that SBC was higher in patients with
TdP than those without (8277421 ng/ml vs. 4867363 ng/ml,
p¼0.02). In addition, all patients with TdP had a high SBC
(Z500 ng/ml) [16]. Therefore, we selected the cutoff point as
500 ng/ml. Our results demonstrated that the QT and QTc were
signiﬁcantly longer in the HSBC group (Z500 ng/ml) than in the
LSBC group (o500 ng/ml) (p¼0.004 and p¼0.016, respectively).
There were more patients with a QT40.5 s in the HSBC group
than in the LSBC group (37.5% vs. 3.4%, p¼0.026), and TdP
occurred in the HSBC group only. An SBC of 500 ng/ml may reﬂect
the threshold for the safe utilization of Bep in this patient
population. However, as Kurita et al. reported, there is a signiﬁ-
cant overlap in SBC between patients with and without TdP: 32%
of patients without TdP also had an SBCZ500 ng/ml [16]. In our
study, 62.5% of the patients in the HSBC group showed a QT
intervalo0.5 s. Recently, Kamakura et al. [18] proposed that a
higher SBC range between 600 and 1000 ng/ml may be suitable
for the safe use of Bep with improving clinical symptoms. Shiga
et al. [19] reported that QTc40.5 was observed in patients with a
plasma concentration of Bep4800 ng/ml. Therefore, further data
and analysis are required to decide the safe levels of SBC.
4.2. Relationship between SBC and QT interval
In this study, we found that SBC was correlated with QT interval
(r¼0.383, p¼0.019) and QTc (r¼0.348, p¼0.034). However, therewas considerable variation in each patient. Several patients had a
normal QT/QTc despite a high SBC (Figs. 2 and 3). Although the
precise reason for this discrepancy remains unknown, it might
partly reﬂect genetic factors. Therefore, SBC could be another maker
for safety management of Bep treatment in addition to QT/QTc
measurement. We recommend reducing Bep dose in patients with a
high SBC irrespective of QT/QTc.
4.3. Relationship between SBC and dose of bepridil
In this study, SBC was not signiﬁcantly related to Bep dose
(r¼0.268, p¼0.11), but SBC was weakly correlated with Bep dose
per kilogram of body weight (r¼0.393, p¼0.015) (Fig. 1). Several
patients had a relatively low SBC despite taking a high dose of Bep
per kilogram of body weight. Compliance with treatment or
individual variation in absorption, metabolism, and/or excretion
may have contributed to this discordance. Fig. 5 shows the
relationship between mean dose of Bep and mean SBC in previous
studies [16–18,20] and our study. Although a dose-dependent
increase in SBC is observed, there is some variation in the
distribution of SBC for a similar dose. The difference in study
population, including body size and underlying heart disease,
may be contributed to the discordance. Large interindividual
differences in SBC were shown even in patients taking same dose
of Bep [18,19]. However, we propose that the SBC range for safe
S. Miura et al. / Journal of Arrhythmia 28 (2012) 187–191 191management needs to be established in a large population
including patients with various types of heart disease.
4.4. Study limitations
The present study had a number of limitations. First, although
we included several patients with valvular heart disease or mild
left ventricular hypertrophy due to hypertension, all subjects in
our study had normal systolic function (LVEF40.6). The safe SBC
range for Bep treatment might be differed among patients with
impaired LV function. Second, the maintenance rate of sinus
rhythm was not different between the high and low SBC groups
in this study. The efﬁcacy of Bep treatment in rhythm control
strategies has been reported [1–8]. However, the J-BAF study
reported the high recurrence rate of AF during Bep treatment as
well as its anti-arrhythmic efﬁcacy [15]. It remains difﬁcult to
precisely evaluate the anti-arrhythmic effects due to the fre-
quency of asymptomatic AF recurrence with Bep treatment [15].
Evaluation of this issue was not an objective of the present study,
and thus it remains to be considered elsewhere. Third, we did not
consider the time interval between taking Bep and SBC measure-
ment. Bep has a long half-life of 33715 h for a single dose [21].
In addition, Sugi et al. [20] reported that SBC was not different
between 2 and 10 h after taking Bep. In this study, we measured
SBC after more than 4 weeks of Bep treatment at the same dose.
Therefore, we believe that the time at which steady-state SBC was
measured did not inﬂuence our results. Fourth, we did not
evaluate the morphological changes in T–U waves. Kurokawa
et al. [22] reported that a newly-appearing negative T–U wave
was an independent predictor of ventricular arrhythmic events in
patients receiving Bep therapy. In our study, only one patient had
an episode of ventricular arrhythmia with QT prolongation and a
fused U or T–U complex but lacked a negative T–U wave (Fig. 4).
In the future, attention should be paid to the morphological
changes in T–U waves during Bep treatment; more clinical
evidence will be necessary to deﬁne the criteria for abnormal
T–U waves. Finally, in the present study, we evaluated only a
limited number of patients at a single center. To deﬁne an SBC
range that will be safe for patients receiving Bep treatment, multi-
center studies of a larger number of patients with various clinical
backgrounds will be necessary.5. Conclusions
In patients receiving Bep treatment, SBC appears to be a useful
measure for the prevention of proarrhythmias in addition to QT
and QTc measurement. An SBC range indicated for safe Bep use
needs to be established.Conﬂict of interest
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